TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05565976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins (Cardiovascular Agents)
Description: Atorvastatin 20mg PO q24h or Pravastatin 20mg PO q24h or Rosuvastatin 10mg PO q24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Antiaggregant
Description: Clopidogrel 75mg PO q24h or Acetylsalicylic acid 100mg PO q24h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Antiaggregant
Description: Clopidogrel 75mg PO q24h or Acetylsalicylic acid 100mg PO q24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidiabetic
Description: Previously established medical treatment for type 2 diabetes will be maintained.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidiabetic
Description: Previously established medical treatment for type 2 diabetes will be maintained.
Study: NCT00203411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda)
Description: 1000mg/m\^2 administered orally twice daily for two weeks followed by one week rest period
Study: NCT04917497

Intervention type: DRUG
Intervention: Levosimendan
Description: Levosimendan was administered according to a standardized treatment protocol. A total dose of 12.5mg or 25mg (corresponding to one or two ampoules) was given at an infusion rate of 0.05 μg/kg/min to 0.2μg/kg/min with or without a loading dose (6 μg/kg or 3 μg/kg over 10 minutes). The decision about total dose, infusion rate and loading dose was at the discretion of the treating physician.
Study: NCT04084340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real transcranial direct current stimulation + therapeutic exercises for urinary incontinence
Description: Real transcranial direct current stimulation associated with therapeutic exercises for urinary incontinence~tDCS: 20 minutes, 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively.
Study: NCT00203411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg IV will be administered every 3 weeks
Study: NCT01925365

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: wholegrain cereals oats (WGO)
Description: Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non wholegrain cereals
Description: Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
Study: NCT02044809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Study: NCT00608517

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Given daily for 1-4 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Given daily for 1-4 days
Study: NCT02044809

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03242148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toffee Nasal Pillows Mask
Description: Participants will be placed on this intervention for a total 14 ± 5 days from Visit 2. Participants will be using the Toffee nasal pillows mask during this treatment arm.
Study: NCT04084340

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence
Description: Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence~tDCS: 20 minutes (30 seconds ON), 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively.
Study: NCT04091334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused ultrasound of the lungs (FLUS) and focused cardiac ultrasound (FoCUS)
Description: FLUS: Scanning 8 zones of the front and lateral of the thorax. Record number of B-lines, consolidations, pneumothorax, pleural effusions.~FoCUS: Scan the heart in different views and record the ejection fraction, size of the right side of the heart, pericardial effusion, tricuspid annular plane systolic excursion (TAPSE), inferior vena cava (IVC) diameter, and IVC collapsibility Index (IVC-CI).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care and evaluation and monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care and evaluation and monitoring
Study: NCT01923012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (Menaquinone)
Study: NCT00632424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone (oral formulation)
Description: Capsules, Oral, Dose escalating (Phase 1), 3 doses on 1 day every 3 weeks, until disease progression or unacceptable toxicity
Study: NCT03899532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Description: Standard manual blood pressure cuff

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No-Remote Ischemic Conditioning
Description: No-Remote Ischemic Conditioning
Study: NCT05396313

Intervention type: DEVICE
Intervention: CRT/ICD
Description: The patients received implantation of CRT/ICD.
Study: NCT03903458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine
Description: First-in-human administration of the combination of Tinostamustine and Nivolumab.
Study: NCT02537847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitafloxacin
Description: The patients in intervention group will receive carbapenem for the first 3 days then sitafloxacin for 7 days. Total of treatment duration is 10 days.
Study: NCT02537847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Control group will be given ertapenem only for 10 days.
Study: NCT00657228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous heparin
Description: Intravenous heparin as an adjunct for the treatment of anaphylactic/anaphylactoid reactions in the Emergency Department.~To determine if a single bolus of intravenous unfractionated heparin (in conjunction with standard therapy) given to patients with anaphylactic/anaphylactoid reactions results in a faster time to recovery when compared to standard therapy alone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) and saline.
Study: NCT00777127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
Study: NCT02631018

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Weight Loss Intervention
Description: 18 session, group-based, 6-month, standard behavioral weight loss intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Enhanced Weight Loss Intervention
Description: 18 session, group-based, 6-month, physical activity enhanced behavioral weight loss intervention
Study: NCT01192984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: Intravenously 8 times at 1-week intervals
Study: NCT01610076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Code Status Video
Description: 10 minute video about Code Status
Study: NCT01729572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-medicine monitoring of medication adherence
Study: NCT01016548

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AS03-adjuvanted H1N1 pandemic influenza vaccine
Description: One dose constitutes 0.5mL of suspended vaccine via the intramuscular route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H1N1 pandemic influenza vaccine
Description: One dose constitutes 0.5mL of suspended vaccine via the intramuscular route.
Study: NCT02682030

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Chest Compression Device (HFCC)
Description: A vest designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Chest Compression Device (HFCC)
Description: A vest designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area.
Study: NCT01339234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill training
Description: Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
Study: NCT02201043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide 150mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide 100mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04527822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse led discharge planning program
Description: a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nurse led discharge planning program
Description: a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan
Study: NCT00214240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMV Immune globulin
Description: CMV IvIg 150mg/kg x 6 doses
Study: NCT04425668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic detailing (AD)
Description: In addition to continuing educational (CE) videos this group will receive up to two personalized, one-on-one, education sessions from an academic detailer. The sessions will last between 15-30 minutes. Each AD visit will consist of: an introduction, a brief needs assessment, key educational messages, a discussion of challenges the provider faces, and giving the provider leave-behind educational materials. The AD visit key educational messages are specific recommendations for opioid-prescribing practice change. When appropriate the detailer will suggest a phone call with Dr. Romesh Nalliah to discuss specific dentistry questions. There may also be a second AD visit if agreed upon by the dentist.
Study: NCT02682030

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cough Assist
Description: A device that aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing.
Study: NCT01816815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1002670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1002670
Study: NCT04180995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)
Description: TORIPALIMAB INJECTION(JS001 ) combined with chemotherapy, 3mg/kg, Q2W,up to 1 years of treatment.
Study: NCT04090437

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation procedure
Description: Catheter ablation procedure using Acutus mapping system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation procedure
Description: Catheter ablation procedure using Acutus mapping system
Study: NCT02618343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPA
Description: IPA Aromatherapy for the experimental arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Zofran will be administered to the Control arm. This is the drug historically administered by prehospital personnel.
Study: NCT04284280

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Routine vs Selective use of Human Milk Donor Fortifier
Description: Infants will be randomized to two groups. Both groups will be fed Premature Human Milk (either Maternal own milk or Premature donor human milk). However, one group will get fortified with Donor Human Milk Fortifier once full feed is reached while the second group will get fortified using the same fortifier only when weight gain is suboptimal.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Routine vs Selective use of Human Milk Donor Fortifier
Description: Infants will be randomized to two groups. Both groups will be fed Premature Human Milk (either Maternal own milk or Premature donor human milk). However, one group will get fortified with Donor Human Milk Fortifier once full feed is reached while the second group will get fortified using the same fortifier only when weight gain is suboptimal.
Study: NCT01164865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE RepleniSH multipurpose disinfecting solution
Description: FDA-approved, multipurpose disinfecting solution used according to provided instructions for cleaning, rinsing, storing, and disinfecting study contact lenses on a daily basis, 2 weeks.
Study: NCT01816815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1002670

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00762931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolve Stimulator and Proximity Lead
Description: An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation
Study: NCT01748331

Intervention type: OTHER
Group type: OTHER
Intervention: Fluid restriction
Description: Patients will be randomized to strict fluid restriction \< 1 L/day versus moderate fluid restriction \< 2.5 L/day

Intervention type: OTHER
Group type: OTHER
Intervention: Fluid restriction
Description: Patients will be randomized to strict fluid restriction \< 1 L/day versus moderate fluid restriction \< 2.5 L/day
Study: NCT04425668

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuing educational
Description: Dentists enrolled in the CE program will serve as the control group. They will have access to the 3 hours of CE content online similar to the AD group; however, they will not receive academic detailing or the opportunity to connect via phone with Dr. Nalliah.~In this group, if the dentists have content-specific questions after participating in the CE program, they may contact MichiganOPENdental@umich.edu for responses appropriately directed to Dr. Nalliah.
Study: NCT01366677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: Three yoga classes per week for 8 weeks.
Study: NCT00834652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 50 mg once a day, which may be increased to 200 mg once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline
Description: 50 mg once a day, which may be increased to 200 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily
Study: NCT01713231

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard-dose vitamin D (400IU per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-dose vitamin D (2000 IU per day)
Study: NCT03316378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: single dose, subcutaneous injection
Study: NCT04894565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: physical therapy 24 hrs after surgery
Study: NCT02326987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
Study: NCT03176459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel + Bupivacaine
Description: EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
Study: NCT01081314

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical Behavior Therapy
Description: Standard Dialectical Behavior Therapy as described in the 2 DBT treatment manuals (Linehan, 1993a,b).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: Standard Dialectical Behavior Therapy as described in the 2 DBT treatment manuals (Linehan, 1993a,b).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD Protocol
Description: A modified version of Prolonged Exposure therapy for PTSD
Study: NCT03732261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and dietary
Description: The 12-week study invention will take place between 6 to 8-weeks postpartum and 18 to 20-weeks postpartum, with a follow-up at one year postpartum. The six-week postpartum time point is to allow for exercise clearance from the participant's obstetrician. The exercise clearance is needed prior to the baseline laboratory measurement. Women will be randomized to an intervention group or minimal care group after all baseline measurements (anthropometrics, cardiovascular fitness test, human milk and blood samples and DXA) at six-weeks postpartum. A random numbers table will be used to stratify by parity and determine groups.
Study: NCT02326987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg
Description: Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
Study: NCT00897169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: A 5-hour oral glucose tolerance test (OGTT) is performed at visit 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: A 5-hour oral glucose tolerance test (OGTT) is performed at visit 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Euglycaemic hyperinsulinaemic clamp
Description: A 4-hour euglycaemic, hyperinsulinaemic clamp is performed at visit 3
Study: NCT03507348

Intervention type: DRUG
Group type: OTHER
Intervention: visits of tocilizumab injection (every 4 weeks, up to 5 visits)
Description: every 4 weeks, up to 5 visits (D-170, D-142, D-114, D-86, D-58).

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab 375 mg/m2 at Day-30
Description: Rituximab 375 mg/m2 at Day-30

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab 375 mg/m2 at Day-30
Description: Rituximab 375 mg/m2 at Day-30

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab 375 mg/m2 at Day-15 (only for donors living)
Description: Rituximab 375 mg/m2 at Day-15
Study: NCT01033929

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rdESAT-6 + rCFP-10 (C-Tb)
Description: rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rdESAT-6 + rCFP-10 (C-Tb)
Description: rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.
Study: NCT02296476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib
Description: Administered orally in a fasted state once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib
Description: Administered orally in a fasted state once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib
Description: Administered orally in a fasted state once daily.